Enanta Pharmaceuticals, Inc.
ENTA
$13.24
-$0.26-1.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -16.32% | -7.82% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -16.32% | -7.82% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -16.32% | -7.82% | |||
| SG&A Expenses | -1.03% | 6.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.91% | -2.87% | |||
| Operating Income | -45.43% | -5.32% | |||
| Income Before Tax | -48.77% | -9.82% | |||
| Income Tax Expenses | 414.29% | -70.83% | |||
| Earnings from Continuing Operations | -48.96% | -9.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -48.96% | -9.66% | |||
| EBIT | -45.43% | -5.32% | |||
| EBITDA | -50.81% | -6.19% | |||
| EPS Basic | -48.71% | -8.55% | |||
| Normalized Basic EPS | -48.51% | -8.89% | |||
| EPS Diluted | -48.71% | -8.55% | |||
| Normalized Diluted EPS | -48.51% | -8.89% | |||
| Average Basic Shares Outstanding | 0.17% | 1.02% | |||
| Average Diluted Shares Outstanding | 0.17% | 1.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||